%0 Journal Article %1 Glass.2006 %A Glass, Bertram %A Kloess, Marita %A Bentz, Martin %A Schlimok, Günter %A Berdel, Wolfgang E. %A Feller, Alfred %A Trümper, Lorenz %A Loeffler, Markus %A Pfreundschuh, Michael %A Schmitz, Norbert %D 2006 %J Blood %K IMISE-Publikationen %N 8 %P 3058–3064 %T Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma %V 107 %X Feasibility, safety, and efficacy of a 4-course high-dose chemotherapy (HDT) protocol including autologous stem cell transplantation (SCT) after courses 2, 3, and 4 was investigated in 110 patients, aged 18 to 60 years, with primary diagnosis of aggressive NHL (aNHL), and lactic dehydrogenase (LDH) levels above normal. At dose level 1 (DL1), course 1 consisted of cyclophosphamide 1500 mg/m2, doxorubicin (Adriamycin) 70 mg/m2, vincristine 2 mg, etoposide 450 mg/m2, and prednisone 500 mg. With courses 2 and 3 cyclophosphamide and etoposide were escalated to 4500 mg/m2 and 600 mg/m2, respectively. With course 4 cyclophosphamide and etoposide were given at 6000 mg/m2 and 1000 mg/m2, respectively. At DL2 etoposide was further increased to 600, 960, 960, and 1480 mg/m2 with courses 1 to 4, respectively. Therapy as per protocol was completed by 81.8\% of patients. Overall survival at 5 years was 67.2\%, freedom from treatment failure (FFTF) was 62.1\%, and treatment-related mortality was 4.5\%. There was a trend to better FFTF at DL2 compared to DL1 (66.9\% versus 54.2\%). Repetitive HDT with escalated CHOP plus etoposide is feasible and effective treatment of patients with aNHL. DL2 of this therapy is being used in an ongoing phase 3 study.

@article{Glass.2006, abstract = {Feasibility, safety, and efficacy of a 4-course high-dose chemotherapy (HDT) protocol including autologous stem cell transplantation (SCT) after courses 2, 3, and 4 was investigated in 110 patients, aged 18 to 60 years, with primary diagnosis of aggressive NHL (aNHL), and lactic dehydrogenase (LDH) levels above normal. At dose level 1 (DL1), course 1 consisted of cyclophosphamide 1500 mg/m2, doxorubicin (Adriamycin) 70 mg/m2, vincristine 2 mg, etoposide 450 mg/m2, and prednisone 500 mg. With courses 2 and 3 cyclophosphamide and etoposide were escalated to 4500 mg/m2 and 600 mg/m2, respectively. With course 4 cyclophosphamide and etoposide were given at 6000 mg/m2 and 1000 mg/m2, respectively. At DL2 etoposide was further increased to 600, 960, 960, and 1480 mg/m2 with courses 1 to 4, respectively. Therapy as per protocol was completed by 81.8\% of patients. Overall survival at 5 years was 67.2\%, freedom from treatment failure (FFTF) was 62.1\%, and treatment-related mortality was 4.5\%. There was a trend to better FFTF at DL2 compared to DL1 (66.9\% versus 54.2\%). Repetitive HDT with escalated CHOP plus etoposide is feasible and effective treatment of patients with aNHL. DL2 of this therapy is being used in an ongoing phase 3 study.}, added-at = {2014-10-15T15:03:49.000+0200}, author = {Glass, Bertram and Kloess, Marita and Bentz, Martin and Schlimok, Günter and Berdel, Wolfgang E. and Feller, Alfred and Trümper, Lorenz and Loeffler, Markus and Pfreundschuh, Michael and Schmitz, Norbert}, biburl = {https://www.bibsonomy.org/bibtex/26e70b8a47a3b39864e82c537b8b1becf/drtester}, interhash = {1946c1e155c682b5bf6d9d3142d129af}, intrahash = {6e70b8a47a3b39864e82c537b8b1becf}, journal = {Blood}, keywords = {IMISE-Publikationen}, number = 8, pages = {3058–3064}, timestamp = {2014-10-15T15:03:49.000+0200}, title = {Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma}, volume = 107, year = 2006 }